Banner
Identification
Name Sargramostim
Accession Number DB00020 (BIOD00035, BTD00035)
Type biotech
Groups approved
Description

Human, recombinant GM-CSF, expressed in yeast. Glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.

Protein structure Db00020
Display: 3D Structure
Protein chemical formula C639H1006N168O196S8
Protein average weight 14434.5000
Sequences
>DB00020 sequence
APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE
LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFD
CWEPVQE

FASTA
Synonyms
Colony-stimulating factor
CSF
GM-CSF
Granulocyte-macrophage colony-stimulating factor precursor
Molgramostin
Salts Not Available
Brand names
Name Company
Immunex
Leucomax (Novartis)
Leukine
Leukine (Berlex Laboratories Inc)
Brand mixtures Not Available
Categories
  • Antineoplastic Agents
  • Immunomodulatory Agents
  • Anti-Infective Agents
CAS number 83869-56-1
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication For the treatment of cancer and bone marrow transplant
Pharmacodynamics Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.
Mechanism of action Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils
Absorption Not Available
Volume of distribution Not Available
Protein binding Not Available
Metabolism Not Available
Route of elimination Not Available
Half life Not Available
Clearance
  • 420 mL/min/m2 [Normal people with liquid LEUKINE (IV)]
  • 431 mL/min/m2 [Normal people with lyophilized LEUKINE (IV)]
  • 549 mL/min/m2 [Normal people with liquid LEUKINE (SC)]
  • 529 mL/min/m2 [Normal people with lyophilized LEUKINE (SC)]
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers Not Available
Packagers
Dosage forms
Form Route Strength
Injection, powder, for solution Intravenous drip
Injection, powder, for solution Subcutaneous
Injection, solution Intravenous drip
Injection, solution Subcutaneous
Prices
Unit description Cost Unit
Leukine 250 mcg vial 204.79 USD vial
Bio-immunex capsule 0.42 USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Country Patent Number Approved Expires (estimated)
Canada 1341150 2000-12-05 2017-12-05
Properties
State liquid
Experimental Properties
Property Value Source
isoelectric point 5.05 Not Available
References
Synthesis Reference Not Available
General Reference Not Available
External Links
Resource Link
UniProt P04141 Link_out
Genbank M13207 Link_out
PharmGKB PA164748631 Link_out
RxList http://www.rxlist.com/cgi/generic/sargramostim.htm Link_out
Drugs.com http://www.drugs.com/cdi/sargramostim.html Link_out
Wikipedia http://en.wikipedia.org/wiki/Sargramostim Link_out
ATC Codes
  • L03AA09
AHFS Codes Not Available
PDB Entries
FDA label Not Available
MSDS Not Available
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Targets

1. Granulocyte-macrophage colony-stimulating factor receptor alpha chain

Pharmacological action: yes
Actions: agonist

Low affinity receptor for granulocyte-macrophage colony- stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells

Organism class: human
UniProt ID: P15509 Link_out
Gene: CSF2RA Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7. Pubmed
  2. Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem. 2006 Aug 4;281(31):22421-6. Epub 2006 Jun 7. Pubmed
  3. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. Pubmed
  4. Xiao R, Zhang R, Wang YL, Zhu ZL, Chen T, Yang JH: [Expression of soluble GM-CSF-Ralpha in patients with acute myeloid leukemia] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):225-7. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Interleukin-3 receptor alpha chain

Pharmacological action: yes
Actions: agonist

This is a receptor for interleukin-3

Organism class: human
UniProt ID: P26951 Link_out
Gene: IL3RA Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007 Aug;35(8):1163-71. Epub 2007 Jun 11. Pubmed
  2. Sakhno LV, Leplina OIu, Tikhonova MA, Raspai ZhM, Gileva IP, Nikonov SD, Zhdanov OA, Ostanin AA, Chernykh ER: [Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis] Probl Tuberk Bolezn Legk. 2007;(3):42-6. Pubmed
  3. Ward KA, Stewart LA, Schwarer AP: CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy. 2006;8(2):130-40. Pubmed
  4. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. Pubmed

3. Cytokine receptor common beta chain

Pharmacological action: yes
Actions: agonist

High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor

Organism class: human
UniProt ID: P32927 Link_out
Gene: CSF2RB Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Shen Y, Baker E, Callen DF, Sutherland GR, Willson TA, Rakar S, Gough NM: Localization of the human GM-CSF receptor beta chain gene (CSF2RB) to chromosome 22q12.2—>q13.1. Cytogenet Cell Genet. 1992;61(3):175-7. Pubmed

4. Syndecan-2

Pharmacological action: unknown
Actions: agonist

Cell surface proteoglycan that bears heparan sulfate

Organism class: human
UniProt ID: P34741 Link_out
Gene: SDC2 Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Modrowski D, Basle M, Lomri A, Marie PJ: Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem. 2000 Mar 31;275(13):9178-85. Pubmed

5. Bone-marrow proteoglycan

Pharmacological action: unknown

Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA

Organism class: human
UniProt ID: P13727 Link_out
Gene: PRG2 Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Menon K, Wu Y, Haas J, Sahu SK, Yang B, Zaheer A: Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice. Neurosci Res. 2007 Jun;58(2):156-63. Epub 2007 Feb 22. Pubmed
  2. Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006 Mar;117(3):590-6. Epub 2006 Feb 8. Pubmed
  3. Kang JH, Lee DH, Seo HM, Park JS, Nam KH, Shin SY, Park CS, Chung IY: Regulation of Functional Phenotypes of Cord-blood-derived Eosinophils by {gamma}-secretase Inhibitor. Am J Respir Cell Mol Biol. 2007 Jun 28;. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on October 31, 2010 08:54